For the first nine months of 2025, Roche’s overall sales grew 7% at constant currencies to 45.9 billion Swiss francs (nearly ...

Swiss pharma major Roche (ROG: SIX) has entered a global exclusive licensing agreement with China’s Qyuns Therapeutics for ...

With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...

Wondering if Roche Holding might be a hidden gem in today’s market? You’re not alone, as many investors are taking a closer ...

Swiss pharma giant Roche today released financial results for the first nine months of 2025, showing that group sales grew by ...

Roche has headed back to China to pen a licensing deal worth over $1 billion biobucks for the rights to a clinical-stage bispecific antibody for respiratory diseases. | Roche has headed back to China ...

Two of the world’s largest pharmaceutical companies, Pfizer (New York, US) and Roche (Basel, Switzerland), have unveiled more ...

Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions the Japanese business took earlier this ...

Shares of Swiss drugmaker Roche fell on Thursday after sales of its new treatments for eye disease and haemophilia ...

Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388 Collaboration will complement Roche's ...

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF). Under the ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...